ocgn-20200603xex991 Our Mission is to develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck Forward Looking Statement This presentation contains forward-looking statements that involve substantial

Our Mission is to develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck

Breakthrough Modifier Gene Therapy Platform Addressing Multiple Diseases with One Product 6

OCU200: Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Wet AMD Novel Biologic Offering Benefits Beyond Anti-VEGF 18

A Bold Vision to Cure Blindness Diseases with Gene Therapies For more information, contact: Kelly Beck Vice President, Investor Relations & Administration kelly.beck@ocugen.com